Methods and compounds for reducing threonyl-tRNA synthetase activity
AssigneeUniversity of Vermont and State Agricultural College
InventorsChristopher Francklyn, Karen M. Lounsbury, Jason Botten
Life of this patent
Estimating the term…
Abstract
The invention includes, in part, methods and compounds for treating diseases and conditions characterized by elevated threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is elevated as compared to normal. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess a treatment for a disease or condition characterized by elevated TARS activity.
Claims12
A composition comprising a nucleic acid molecule encoding a threonyl-tRNA synthetase (TARS) activity-inhibiting compound, wherein the TARS activity-inhibiting compound comprises a protein that comprises a threonyl-tRNA synthetase (TARS)-activity-inhibiting polypeptide fragment with TARS inhibiting activity, wherein the amino acid sequence of the TARS-activity-inhibiting polypeptide fragment is:
- (1) a TARS NI domain sequence consisting of amino acids 82-143 of SEQ ID NO:
- 2, (2) a modified sequence of (1) with at least 98% identity to the amino acid sequence of the TARS NI domain sequence and capable of binding a VHL polypeptide;
- or (3) the polypeptide set forth as SEQ ID NO:
- 7, and further wherein the nucleic acid molecule is in a vector.
A method of decreasing angiogenesis in prostate cancer cells, the method comprising:
- contacting prostate cancer cells with an effective amount of a composition comprising a nucleic acid molecule encoding a tRNA synthetase (TARS)-activity-inhibiting polypeptide fragment with TARS inhibiting activity, wherein the amino acid sequence of the TARS-activity-inhibiting polypeptide fragment is:
- (1) a TARS NI domain sequence consisting of amino acids 82-143 of SEQ ID NO:
- 2, (2) a modified sequence of (1) with at least 98% identity to the amino acid sequence of the TARS NI domain sequence and capable of binding a VHL polypeptide;
- or (3) the polypeptide set forth as SEQ ID NO:
- 7, to decrease angiogenesis in the cells, wherein the nucleic acid molecule is in a vector.
A method of decreasing angiogenesis in ovarian cancer cells, the method comprising:
- contacting ovarian cancer cells with an effective amount of a composition comprising a nucleic acid molecule encoding a tRNA synthetase (TARS)-activity-inhibiting polypeptide fragment with TARS inhibiting activity, wherein the amino acid sequence of the TARS-activity-inhibiting polypeptide fragment is:
- (1) a TARS NI domain sequence consisting of amino acids 82-143 of SEQ ID NO:
- 2, (2) a modified sequence of (1) with at least 98% identity to the amino acid sequence of the TARS NI domain sequence and capable of binding a VHL polypeptide;
- or (3) the polypeptide set forth as SEQ ID NO:
- 7, to decrease angiogenesis in the cells, wherein the nucleic acid molecule is in a vector.
Dependencies are inferred from the claim text.